Antiretroviral drug pharmacokinetics in hepatitis with hepatic dysfunction.

Drug disposition in pathophysiological conditions. Curr Drug Metab (2012) 0.90

Zidovudine and Lamivudine for HIV Infection. Clin Med Rev Ther (2010) 0.89

Association of saquinavir plasma concentrations with side effects but not with antiretroviral outcome in patients infected with protease inhibitor-susceptible human immunodeficiency virus type 1. Antimicrob Agents Chemother (2007) 0.87

Influence of CYP2C19 polymorphism on the pharmacokinetics of nelfinavir and its active metabolite. Br J Clin Pharmacol (2009) 0.78

Pharmacokinetics of Single-Dose Dolutegravir in HIV-Seronegative Subjects With Moderate Hepatic Impairment Compared to Healthy Matched Controls. Clin Pharmacol Drug Dev (2013) 0.78

Impact of new treatment options for hepatitis C virus infection in liver transplantation. World J Gastroenterol (2015) 0.77

Abacavir dosing with hepatic dysfunction. Clin Infect Dis (2005) 0.76

Evaluation of quantitative liver function tests in HIV-positive patients under anti-retroviral therapy. Eur J Med Res (2009) 0.76

Relevance of Liver Failure for Anti-Infective Agents: From Pharmacokinetic Alterations to Dosage Adjustments. Ther Adv Infect Dis (2014) 0.75

Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin Infect Dis (2003) 3.07

Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047. AIDS (2002) 2.59

Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society-USA panel. J Acquir Immune Defic Syndr (2002) 1.98

Protein binding in antiretroviral therapies. AIDS Res Hum Retroviruses (2003) 1.67

Position paper on therapeutic drug monitoring of antiretroviral agents. AIDS Res Hum Retroviruses (2002) 1.66

Modeling long-term HIV dynamics and antiretroviral response: effects of drug potency, pharmacokinetics, adherence, and drug resistance. J Acquir Immune Defic Syndr (2005) 1.52

Comparison of two indinavir/ritonavir regimens in the treatment of HIV-infected individuals. J Acquir Immune Defic Syndr (2004) 1.48

Drug/Drug interaction between lopinavir/ritonavir and rosuvastatin in healthy volunteers. J Acquir Immune Defic Syndr (2008) 1.24

Hepatotoxicity and gastrointestinal intolerance when healthy volunteers taking rifampin add twice-daily atazanavir and ritonavir. J Acquir Immune Defic Syndr (2009) 1.11

Interactions between antiretroviral drugs and drugs used for the therapy of the metabolic complications encountered during HIV infection. Clin Pharmacokinet (2002) 1.11

Pharmacodynamics of antiretroviral agents in HIV-1 infected patients: using viral dynamic models that incorporate drug susceptibility and adherence. J Pharmacokinet Pharmacodyn (2006) 1.05

The pharmacokinetics of amprenavir, zidovudine, and lamivudine in the genital tracts of men infected with human immunodeficiency virus type 1 (AIDS clinical trials group study 850). J Infect Dis (2002) 1.01

Effect of concomitantly administered rifampin on the pharmacokinetics and safety of atazanavir administered twice daily. Antimicrob Agents Chemother (2007) 0.98

The pharmacology of antiretroviral nucleoside and nucleotide reverse transcriptase inhibitors: implications for once-daily dosing. J Acquir Immune Defic Syndr (2005) 0.94

Pharmacokinetic interactions between indinavir plus ritonavir and calcium channel blockers. Clin Pharmacol Ther (2005) 0.93

Pharmacokinetic interaction between nelfinavir and pravastatin in HIV-seronegative volunteers: ACTG Study A5108. AIDS (2006) 0.90

A randomized, placebo-controlled trial of abacavir intensification in HIV-1-infected adults with virologic suppression on a protease inhibitor-containing regimen. HIV Clin Trials (2011) 0.89

Enantioselectivity of inhibition of cytochrome P450 3A4 (CYP3A4) by ketoconazole: Testosterone and methadone as substrates. Chirality (2004) 0.87

Amdoxovir versus placebo with enfuvirtide plus optimized background therapy for HIV-1-infected subjects failing current therapy (AACTG A5118). Antivir Ther (2006) 0.84

Indinavir protein-free concentrations when used in indinavir/ritonavir combination therapy. AIDS (2005) 0.77

Therapeutic drug monitoring: pharmacologic considerations for antiretroviral drugs. Curr HIV/AIDS Rep (2005) 0.77

Editorial comment: drug-drug interactions, hepatitis C, and mitochondrial toxicity. AIDS Read (2003) 0.76

Determination of the absolute configuration and solution conformation of the antifungal agents ketoconazole, itraconazole, and miconazole with vibrational circular dichroism. Chirality (2005) 0.76

Stereoselective determination of the epimer mixtures of itraconazole in human blood plasma using HPLC and fluorescence detection. Chirality (2011) 0.75

Abacavir pharmacokinetics in hepatic dysfunction. Clin Infect Dis (2005) 0.75